Melanocyte Protein PMEL: H1 2018 Pipeline Review, Covering Key Players Antigen Express, Scancell Holdings and Vault Pharma - ResearchAndMarkets.com

DUBLIN--()--The "Melanocyte Protein PMEL - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The report provides a snapshot of the global therapeutic landscape for Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL).

The report reviews targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved in Melanocyte Protein PMEL targeted therapeutics and enlists all their major and minor projects.

The report assesses Melanocyte Protein PMEL targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news and deals related to Melanocyte Protein PMEL targeted therapeutics.

Companies Mentioned

  • Antigen Express Inc
  • Scancell Holdings Plc
  • Vault Pharma Inc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Overview
  4. Therapeutics Development
  5. Products under Development by Stage of Development
  6. Products under Development by Therapy Area
  7. Products under Development by Indication
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Therapeutics Assessment
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Companies Involved in Therapeutics Development
  14. Drug Profiles
  15. Dormant Products
  16. Discontinued Products
  17. Product Development Milestones
  18. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/79jr79/melanocyte?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs, Skin Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs, Skin Cancer Drugs